Core Insights - The SYMON-I study indicates that IL-6 levels measured within 24 hours of sepsis or septic shock diagnosis can predict patient mortality up to 28 days [1][11] - Secondary outcomes of the study reveal that IL-6 is a more reliable predictor of mortality than traditional clinical tests like lactate and SOFA [2] - The SYMON clinical study program aims to enhance understanding of IL-6 as a key biomarker for managing sepsis, potentially improving patient survival rates [3][5] Company Overview - Bluejay Diagnostics is focused on developing rapid and accessible biomarker testing, with its lead product candidate being the Symphony IL-6 Test for sepsis triage [13][14] - The company plans to initiate the SYMON-II pivotal clinical study in Q3 2024, with the intention of using the results to support a 510(k) application to the FDA in 2025 [12] - Bluejay Diagnostics aims to improve clinical outcomes through timely and precise diagnostic tests, with results from the SYMON studies expected to be presented at national scientific meetings and published in peer-reviewed journals [12][14]
SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients